<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03325114</url>
  </required_header>
  <id_info>
    <org_study_id>66282</org_study_id>
    <secondary_id>1K23DK114477-01</secondary_id>
    <nct_id>NCT03325114</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Chlorthalidone in Type 1 Diabetes</brief_title>
  <official_title>Safety and Efficacy of Chlorthalidone to Reduce Urinary Calcium Excretion in Adolescents/Yount Adult With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label study will determine if chlorthalidone is safe and effective for the use of
      reducing urinary calcium excretion over 4 weeks in subjects with type 1 diabetes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 diabetes (T1D) is associated with increased urinary calcium loss, which may contribute
      to the low bone mineral density and increased fracture risk observed in patients with this
      condition. Chlorthalidone is a thiazide-like diuretic that is commonly used to reduce urinary
      calcium excretion in other conditions such as idiopathic hypercalciuria. Its safety and
      efficacy has not been specifically tested in an adolescent type 1 diabetes population.

      T1D subjects with hypercalciuria and who meet inclusion/exclusion criteria will be given
      chlorthalidone daily. Blood and urine tests, blood pressure, and glycemic control will be
      assessed at weekly study visits for 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Calcium Excretion</measure>
    <time_frame>Assessed at baseline and at 4 weeks</time_frame>
    <description>Change in 24 hour urine calcium excretion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypokalemia</measure>
    <time_frame>Assessed weekly for up to 4 weeks or until hypokalemia develops</time_frame>
    <description>Serum potassium decreased to &lt;3.5 milliequivalent/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypercalcemia</measure>
    <time_frame>Assessed weekly for up to 4 weeks or until hypercalcemia develops</time_frame>
    <description>Serum calcium increased to &gt;10.5 mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hyperglycemia</measure>
    <time_frame>Assessed at baseline and at 4 weeks</time_frame>
    <description>Change in serum fructosamine</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Hypercalciuria</condition>
  <arm_group>
    <arm_group_label>Chlorthalidone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Chlorthalidone 12.5-50 mg by mouth daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone</intervention_name>
    <description>Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks</description>
    <arm_group_label>Chlorthalidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of T1D

          -  Age 12-21 years

          -  Tanner Stage 2 or greater pubertal development

          -  Urine calcium excretion ≥ 4 mg/kg/day

          -  Able to swallow pills

        Exclusion Criteria:

          -  BMI &gt; 99th percentile for age (&lt;18 years) or BMI &gt;35 kg/m2 (≥ 18 years)

          -  Coexistent conditions that may affect calcium metabolism including:

               -  celiac disease

               -  Graves' Disease

               -  Addison's disease

               -  hypo- or hyperparathyroidism

          -  History of diabetes related complications including:

               -  neuropathy

               -  retinopathy

               -  nephropathy

               -  gastroparesis

          -  History of oral or inhaled corticosteroid use for ≥ 5 consecutive days within the past
             month

          -  History of any diuretic use within the past month

          -  Laboratory abnormalities on screening bloodwork including:

               -  estimated glomerular filtration rate &lt;90 mL/min per 1.73 m2 of body surface area

               -  serum calcium &gt;10.5 mg/dL

               -  serum potassium &lt;3.5 mmol/L

          -  Systolic or diastolic blood pressure &lt;5th percentile for age and sex50 for age &lt;18
             years or systolic &lt;90 mmHg or diastolic blood pressure &lt;60 mmHG for age ≥18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>David Weber</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <keyword>hypercalciuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypercalciuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorthalidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be available in aggregate. No plan to share individual data at present.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

